Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease

NCT04004429 is registered in ClinicalTrials.gov with SynAct Pharma Aps as lead sponsor.

NCT NCT04004429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04004429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease
Lead sponsor
SynAct Pharma Aps
Phase
Phase 2
Overall status
Completed
Start date
August 26, 2019
Completion date
November 16, 2021
Enrollment
105 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis